The US Food and Drug Administration (FDA) has approved a drug for heart failure manufactured by Texas-based Lexicon Pharma, it was reported on Saturday.
Sotagliflozin, an oral drug, is the company's first to be approved by the US health agency. It will be sold under the brand name Inpefa. An earlier drug from the firm, which is an add-on to insulin therapy for type 1 diabetes, had failed to get US approval.
The drug is aimed at a broad treatment of heart failure diseases, including in adult patients with type 2 diabetes.
Calliditas Therapeutics' setanaxib receives US FDA orphan drug designation
Evommune signs strategic collaboration with Maruho Co
IDEAYA Biosciences' IDE161 receives US FDA fast track designation
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Sanofi granted Priority Review for EoE treatment in young children
Valneva secures USD32m IXIARO vaccine contract with US DoD
Sanofi's ALTUVIIIO gains Japanese approval as haemophilia A factor VIII therapy
Seagen and Astellas Pharma report positive outcomes in advanced bladder cancer trial
Mabwell's 9MW3011 receives US FDA Fast Track Designation
89bio receives FDA Breakthrough Therapy Designation for pegozafermin in NASH treatment
Hepagene Therapeutics' HPG7233 IND application receives US FDA approval
Pulmatrix PUR3100 investigational new drug application receives US FDA acceptance
BeiGene regains full rights to anti-PD-1 antibody TEVIMBRA (tislelizumab) from Novartis